BEGIN:VCALENDAR
VERSION:2.0
PRODID:Linklings LLC
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
X-LIC-LOCATION:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20241017T183512Z
LOCATION:Harbor Ballrooms D-I
DTSTART;TZID=America/Los_Angeles:20241015T104800
DTEND;TZID=America/Los_Angeles:20241015T110600
UID:ncs_NCS 2024_sess136_abs202@linklings.com
SUMMARY:The ExTINGUISH Trial: A Phase-2B randomized placebo-controlled tri
 al of inebilizumab in anti-NMDA receptor encephalitis
DESCRIPTION:General Session\n\nKa-Ho Wong (University of Utah, Veterans Af
 fairs Salt Lake City); Gregory Day (Mayo Clinic in Florida); James Torner 
 (University of Iowa); Merit Cudkowicz (Massachusetts General Brigham); Chr
 istopher Coffey (University of Iowa); Sophie Cho (NIH/NINDS); Ursula Utz (
 NIH); Eric Klawiter (MGB); J. Robinson Singleton (University of Utah, Vete
 rans Affairs Salt Lake City); Dana Mitchell (University of Indiana); Susan
 nah Cahalan (Indepenent Journalist/Patient Advocate); Janel Fedler and Dix
 ie Ecklund (University of Iowa); David Klements (MGB); Michele Costigan an
 d Brenda Pearson (University of Iowa); Erin Steinhart and Christina Desir 
 (MGB); Maarten Titulaer (Erasmus Medical Center); and Stacey Clardy (Unive
 rsity of Utah, Veterans Affairs Salt Lake City)\n\nFocus Area: CNS Infecti
 ons/Inflammatory\n\nSession Chairs: Sherif Mahmoud (University of Alberta,
  School of Public Health) and Molly McNett (The Ohio State University)
END:VEVENT
END:VCALENDAR